BiotechTube

Evolocumab + Placebo

Phase 1Recruiting
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Abdominal Aortic Aneurysm

Conditions

Abdominal Aortic Aneurysm

Trial Timeline

Jul 1, 2026 → Feb 28, 2028

NCT ID
NCT06081153

About Evolocumab + Placebo

Evolocumab + Placebo is a phase 1 stage product being developed by Amgen for Abdominal Aortic Aneurysm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06081153. Target conditions include Abdominal Aortic Aneurysm.

What happened to similar drugs?

6 of 20 similar drugs in Abdominal Aortic Aneurysm were approved

Approved (6) Terminated (1) Active (14)
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
✅Tigecycline + Imipenem/cilastatinPfizerApproved
✅tigecyclinePfizerApproved
✅Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (13)

NCT IDPhaseStatus
NCT06081153Phase 1Recruiting
NCT03872401Phase 3Completed
NCT03433755Phase 3Terminated
NCT03515304Phase 2Completed
NCT02833844Phase 3Completed
NCT02729025Phase 3Completed
NCT02392559Phase 3Completed
NCT01813422Phase 3Completed
NCT01764633Phase 3Completed
NCT01763918Phase 3Completed
NCT01588496Phase 2/3Completed
NCT01375751Phase 2Completed
NCT01133522Phase 1Completed

Competing Products

20 competing products in Abdominal Aortic Aneurysm

See all competitors
ProductCompanyStageHype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3
36
HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
35
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactamMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
40
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral TabletMerckPhase 2/3
42
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3
40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
ACZ885 + PlaceboNovartisPhase 2
27
tigecyclinePfizerPhase 3
40
recombinant human growth hormonePfizerPhase 3
40
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
35
Ceftazidime-avibactam + metronidazole + MeropenemPfizerPhase 3
40